-
Cofrogliptin Tablets Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Cofrogliptin Tablets (trade name: 倍长平) of Haisco Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA. It is indicated for improving the blood glucose control for adult patients with type 2 diabetes.
-
Golidocitinib Capsules Approved with Conditions for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Golidocitinib capsule (trade name:高瑞哲) of Dizal (Jiangsu) Pharmaceuticals Co. Ltd. is approved with condition for marketing through the priority review and approval procedure by China NMPA. This drug is indicated as a single agent for adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) who have received at least one line of systemic treatment.
-
Bevifibatide Citrate Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the he Category 1 innovative drug Bevifibatide Citrate Injection (trade name: 贝塔宁/BETAGRIN) of Bio-Thera Solutions, Ltd. is approved for marketing by China NMPA.
-
Fultagliptin Benzoate Tablets Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Fultagliptin Benzoate Tablets (trade name: 信立汀) of Shenzhen Salubris Pharmaceuticals Co., Ltd. is approved by China NMPA.
-
Fulzerasib Tablets Approved with Conditions for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Fulzerasib Tablets (trade name:达伯特) of Innovent Biologics, Inc. is approved with condition for marketing through the priority review and approval procedure by China NMPA.
-
NMPA Re-elected as a Member of the ICH Management Committee
2025-02-19
On June 4, 2024, the plenary session of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) was held in Fukuoka, Japan, at which the National Medical Products Administration (NMPA) was elected as a member of the ICH Management Committee for the third time.
